Earticle

초록

영어

Health insurance review & Assessment service (HIRA) has enforced cutting the drug costs when physicians prescribe split extended release drugs, starting from December, 2010. The objective of this study is to analyze extended release and enteric coated drugs on pharmaceutical reimbursement list in Korea, and to investigate the impact and barriers of the health insurance review on splitting extended-release formulation drugs. By using the ingredient code, extended release and enteric coated formulations make up 7.8% of all drugs in April, 2011. The most frequently used drugs are agent affecting circulatory and digestive system. From the extended release and enteric coated formulations (n=112), 34.8% (n=39) were not available in other dosage forms. According to questionnaire survey for 169 pharmacists (response rate: 73.8%), the rate of splitting and crushing of extended release and enteric coated drugs decreased. When pharmacists correct physician’s prescription errors, the biggest problem was lack of other dosage forms. So it is necessary to develop variety of other dosage forms, and computerized checking system for splitting extended-release drugs. It is also important to inform physicians and patients in regard to the problems of split prescription of extended release and enteric coated drugs.

목차

Abstract
 연구 방법
  약제급여목록의 서방형, 장용성 제제 특성 분석
  서방형, 장용성 제제에 대한 약사 대상 설문 조사
 연구 결과
  약제급여목록의 서방형, 장용성 제제 분석
  서방형, 장용성 제제 분할 처방의 변화와 장애요인 분석
 고찰 및 결론
 감사의 말씀
 참고문헌

키워드

저자

• 장혜민 [ Hye Min Jang | 숙명여자대학교 임상약학대학원 ] Correspondence
• 이의경 [ Eui Kyung Lee | 숙명여자대학교 임상약학대학원 ] Correspondence

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615